EvaluatePharma predicted that Abbott Laboratories and Eisai's rheumatoid arthritis medicine Humira will replace Pfizer's Lipitor as the world's best-selling drug after the cholesterol treatment's patent expires next year. Although Humira is not likely to surpass Lipitor's $13.7 billion in sales in 2006, it is expected to generate $10.1 billion by 2016, the research firm said, followed by Roche Holding's cancer drug Avastin at $8.9 billion.

Related Summaries